Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences

ANN ARBOR, MI / ACCESSWIRE / March 12, 2024 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the presentation of veterinary education programs scheduled at the upcoming Fetch dvm360 Veterinary Conference and subsequent dvm360 Fetch programs.

“The ‘Fetch’ series of veterinarian Continuing Education (CE) programs by dvm360 is the ideal format for presenting Zomedica’s groundbreaking technologies to animal healthcare professionals, and our close relationship with this organization provides us with an exceptional opportunity to bring awareness to veterinarians about the many ways Zomedica’s products and services can benefit them and their patients,” commented Nicole Westfall, Zomedica’s Senior Vice President of Marketing. “The Charlotte meeting is the first in a series of five annual dvm360 CE meetings across the country, with thousands of animal healthcare professionals in attendance. Zomedica will be sponsoring multiple educational seminars to support animal health education at these meetings this year.”

“Recent publications highlighting the efficacy of Zomedica’s PulseVet^® shock wave platform and TRUFORMA^® Bulk Acoustic Wave diagnostic platform, as well as a rapidly growing successful customer base, ensure that we are staying busy at these meetings,” commented Kevin Klass, Zomedica’s Senior Vice President of Sales. “We are grateful to the veterinary leaders that are supporting our educational efforts with their time and enthusiastic interaction with our team as we continue to execute our mission of meeting the needs of clinical veterinarians in ways that promote both patient and practice health.”

Zomedica will be attending and exhibiting at the Fetch Charlotte Annual Conference from March 18 – 21, 2024 at Booth #223, which will feature the following presentations, sponsored by Zomedica, from leaders in the field of veterinary medicine:

• David Dycus, DVM, MS, CCRP, DACVS-SA – “Osteoarthritis Updates Part II: Thinking Outside the Box for Management”
• Fred Wininger, VMD, MS & Adam Christman, DVM, MBA – “From Stone Ages to Modern Marvels! Revolutionizing Veterinary Care Through Technology”
• Robert Schick, DVM, DACVD – “What’s Old and New in Dermatology Labs”
• Matthew Brunke, DVM, CCRP, CVPP, CVA, CCMT – “Overview of Common Neurological Conditions in Veterinary Rehab and A Helpful Targeted Treatment”
• Heidi Lobprise, DVM, DAVDC – “Inflammation and Pain in the Oral Cavity”

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://m.facebook.com/zomedica
• X (formerly Twitter): https://twitter.com/zomedica
• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward Looking Statements

Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on accesswire.com